target/AChE/1

AChE BChE MAO-B-IN-1 is a reversible, non-time-dependent inhibitor of AChE, BChE and MAO-B that crosses the blood-brain barrier and exhibits inhibitory effects on hAChE, hBChE and hMAO-B with IC50s of 7.31, 0.56 and 26.1 μM, respectively. 1 had a neuroprotective effect and was not significantly cytotoxic.

Target 1 has a wide range of applications in life science related research.

AChE/MAO-IN-1 is a potent inhibitor of human acetylcholinesterase (AChE), monoamine oxidase A (MAO-A), and monoamine oxidase B (MAO-B), demonstrating inhibitory concentrations (IC50) of 0.0248 μM, 0.0409 μM, and 0.1108 μM against AChE, MAO-A, and MAO-B, respectively.

Dual AChE-MAO B-IN-1 (compound 15) is a safe, metabolically stable neuroprotective agent.Dual AChE-MAO B-IN-1 is a potent, orally active CNS-permeable inhibitor of human AChE (IC50=550 nM) and MAO-B (IC50=8.2 nM), and has low in vitro activity against AChE and MAO-B with IC50 values of 550 nM, 8.2 nM respectively.

AChE/BChE-IN-1 is a potent dual inhibitor of acetylcholinesterase and butyrylcholinesterase with blood-brain barrier permeability, exhibiting an IC50 value of 1.06 and 7.3 nM for hAChE and hBChE, respectively, and showing antioxidant effects. AChE/BChE-IN-1 can be used in Alzheimer's disease research.

AChE/BChE/BACE-1-IN-2 (Compound 4o) exhibits remarkable antioxidant potential and considerable binding capability towards PAS-AChE. AChE/BChE/BACE-1-IN-2 is an orally active AChE, BACE-1 and BChE inhibitor with IC 50 values of 0.069, 0.097 and 0.127 μM against hAChE, hBACE-1 and hBChE, respectively. AChE/BChE/BACE-1-IN-2 shows potential disassembly of Aβ aggregates and neuroprotective activity against Aβ-induced stress with excellent brain permeation [1].

AChE/PDE4-IN-1 (compound 12c) is a highly effective and specific dual inhibitor of PDE4 and AChE, with IC50 values of 0.28 μM and 1.88 μM for AChE and PDE4D, respectively. This compound demonstrates notable potential in reducing neuroinflammation associated with Alzheimer's disease research [1].

AChE/BACE1/GSK3β-IN-1 is an orally active, blood-brain barrier-transparent, moderately bioavailable triple inhibitor of AChE/BACE1/GSK3β. AChE/BACE1/GSK3β-IN-1 can be used to study Alzheimer's disease (AD).

COX-2-IN-23 (compound A10) is a potent inhibitor of AChE (IC50: 0.12 nM) and HDAC (IC50: 0.23 nM).COX-2-IN-23 exhibits antioxidant and metal chelating properties.COX-2-IN-23 can be used to study Alzheimer's disease.

AChE/BChE/BACE-1-IN-1 (Compound 4k) is an orally active inhibitor that targets acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and β-site amyloid precursor protein cleaving enzyme 1 (BACE-1). It displays IC50 values of 0.058 μM, 0.082 μM, and 0.115 μM against hAChE, hBChE, and hBACE-1, respectively. AChE/BChE/BACE-1-IN-1 exhibits significant binding affinity with PAS-AChE, excellent ability to cross the blood-brain barrier, potential disassembly of amyloid-beta (Aβ) aggregates, and neuroprotective properties against Aβ-induced stress. Moreover, AChE/BChE/BACE-1-IN-1 demonstrates remarkable antioxidant capabilities [1].

AChE/GSK-3β-IN-1 is a potent dual AChE/GSK-3β inhibitor that crosses the blood-brain barrier and acts on hAChE (IC50: 1.2 nM), hBChE (IC50: 149.8 nM) and hGSK-3β (IC50: 22.4 nM). AChE/GSK-3β-IN-1 is able to occupy the ATP binding site of DYRK1A. aChE/GSK-3β-IN-1 exhibits high kinase selectivity for the CMGC kinase family. aChE/GSK-3β-IN-1 inhibits ROS expression and reduces oxidative stress. aChE/GSK-3β-IN-1 can be used to study Alzheimer's disease.

AChE/hCA I/II-IN-1 (Compound 6) is a potent AChE/Hca inhibitor with IC50 values of 22.21, 60.79 and 66.64 nM for AChE, Hca Ⅰ and Hca Ⅱ. AChE/hCA I/II-IN-1 can be used in glaucoma, Alzheimer's disease, and diabetes rsearch[1].

sEH/AChE-IN-1 (Compound 12a) is a dual inhibitor of soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE). sEH/AChE-IN-1 has a cumulative effect against neuroinflammation and memory impairment. sEH/AChE-IN-1 has shown research potential in Alzheimer's disease (AD).

AChE/Aβ-IN-1 (compound 32) is a potent, orally active acetylcholinesterase (AChE) inhibitor with an IC50 of 86 nM and an NMDA receptor antagonist targeting the GluN1-1b/GluN2B subunit combination with an IC50 of 3.876 μM. Additionally, it impedes Aβ aggregation, exhibits favorable blood-brain barrier permeability, offers neuroprotection, and enhances cognitive and spatial memory in rat models [1].

AChE/Nrf2 modulator 1, an orally active compound, serves as a modulator of acetylcholinesterase (AChE) and nuclear factor erythroid 2-related factor 2 (Nrf2). It exhibits Nrf2 inductive activity alongside inhibitory effects on eeAChE and hAChE, demonstrating IC 50 values of 0.07 μM and 0.38 μM, respectively. This compound is applicable in Alzheimer's disease research.

AChE/BuChE-IN-1, a selective butyrylcholinesterase (BuChE) inhibitor derived from chrysin, exhibits a potent efficacy with an IC50 of 0.48 μM against BuChE and a lesser inhibitory effect on acetylcholinesterase (AChE) with an IC50 of 7.16 μM. It demonstrates significant hydroxyl radical (·OH) scavenging activity, achieving an IC50 of 0.1674 μM, and effectively inhibits reactive oxygen species (ROS) and Aβ 1-42 aggregation, including self-aggregation, copper (Cu 2+)-induced, and AChE-induced aggregation. Characterized by high blood-brain barrier (BBB) permeability, bioavailability, and low cellular toxicity, AChE/BuChE-IN-1 holds promising potential for Alzheimer's disease (AD) research.